Anzeige
Erschienen in:
01.08.2012 | Endocrine Tumors
Classification of Parathyroid Cancer
Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2012
Einloggen, um Zugang zu erhaltenAbstract
Purpose
Parathyroid cancer is rare and often has a poor outcome. There is no classification system that permits prediction of outcome in patients with parathyroid cancer. This study was designed to validate two prognostic classification systems developed by Talat and Schulte in 2010 (“Clinical Presentation, Staging and Long-term Evolution of Parathyroid Cancer,” Ann Surg Oncol 2010;17:2156–74) derived from a retrospective literature review of 330 patients.
Methods
This study contains 82 formerly unreported patients with parathyroid cancer. Death due to disease was the primary end point, and recurrence and disease-free survival were the secondary end points. Data acquisition used a questionnaire of predefined criteria. Low risk was defined by capsular and soft tissue invasion alone; high risk was defined by vascular or organ invasion, and/or lymph node or distant metastasis. A differentiated classification system further classified high-risk cancer into vascular invasion alone (class II), lymph node metastasis or organ invasion (class III), and distant metastasis (class IV). Statistical analyses included risk analysis, Kaplan-Meier analysis, and receiver–operating characteristic (ROC) analysis.
Results
Follow-up ranged 2–347 months (mean 76 months). Mortality was exclusive to the high- risk group, which also predicted a significant risk of recurrence (risk ratio 9.6; 95% confidence interval 2.4–38.4; P < 0.0001), with significantly lower 5-year disease-free survival (χ2 = 8.7; P < 0.005 for n = 45). The differentiated classification also provided a good prognostic model with an area under the ROC curve of 0.83 in ROC analysis, with significant impairment of survival between classes (98.6%, 79.2%, 71.4%, 40.0%, P < 0.05 between each class).
Conclusions
This study confirms the validity of both classification systems for disease outcome in patients with parathyroid cancer.